Patrick Wood
Stock Analyst at Morgan Stanley
(3.40)
# 976
Out of 4,761 analysts
77
Total ratings
50%
Success rate
5.96%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Equal-Weight | $75 → $82 | $88.78 | -7.64% | 7 | Feb 14, 2025 | |
| EW Edwards Lifesciences | Maintains: Equal-Weight | $70 → $75 | $73.30 | +2.32% | 8 | Feb 12, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $120 | $104.49 | +14.84% | 5 | Feb 6, 2025 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $104 → $102 | $88.48 | +15.28% | 5 | Dec 6, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Overweight | $45 | $31.00 | +45.16% | 3 | Dec 2, 2024 | |
| GKOS Glaukos | Downgrades: Underweight | $120 | $125.88 | -4.67% | 3 | Dec 2, 2024 | |
| BLCO Bausch + Lomb | Downgrades: Equal-Weight | $19 | $15.75 | +20.63% | 6 | Dec 2, 2024 | |
| PRCT PROCEPT BioRobotics | Initiates: Overweight | $105 | $62.25 | +68.67% | 1 | Dec 2, 2024 | |
| SOLV Solventum | Maintains: Equal-Weight | $60 → $73 | $73.02 | -0.03% | 3 | Nov 11, 2024 | |
| PODD Insulet | Maintains: Overweight | $234 → $317 | $282.80 | +12.09% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $14.38 | -30.46% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $145 | $71.95 | +101.53% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $90.31 | -5.88% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $16.87 | +119.32% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $39 → $30 | $33.82 | -11.30% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $91.09 | -5.59% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $220.56 | -2.52% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $227.43 | +23.11% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $175.64 | - | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $29.60 | +21.62% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $142.40 | - | 5 | Dec 11, 2017 |
DexCom
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $75 → $82
Current: $88.78
Upside: -7.64%
Edwards Lifesciences
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $70 → $75
Current: $73.30
Upside: +2.32%
Boston Scientific
Feb 6, 2025
Maintains: Overweight
Price Target: $100 → $120
Current: $104.49
Upside: +14.84%
The Cooper Companies
Dec 6, 2024
Maintains: Equal-Weight
Price Target: $104 → $102
Current: $88.48
Upside: +15.28%
Tandem Diabetes Care
Dec 2, 2024
Upgrades: Overweight
Price Target: $45
Current: $31.00
Upside: +45.16%
Glaukos
Dec 2, 2024
Downgrades: Underweight
Price Target: $120
Current: $125.88
Upside: -4.67%
Bausch + Lomb
Dec 2, 2024
Downgrades: Equal-Weight
Price Target: $19
Current: $15.75
Upside: +20.63%
PROCEPT BioRobotics
Dec 2, 2024
Initiates: Overweight
Price Target: $105
Current: $62.25
Upside: +68.67%
Solventum
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $60 → $73
Current: $73.02
Upside: -0.03%
Insulet
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $282.80
Upside: +12.09%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $14.38
Upside: -30.46%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $71.95
Upside: +101.53%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $90.31
Upside: -5.88%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $16.87
Upside: +119.32%
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $33.82
Upside: -11.30%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $91.09
Upside: -5.59%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $220.56
Upside: -2.52%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $227.43
Upside: +23.11%
Dec 4, 2023
Upgrades: Overweight
Price Target: n/a
Current: $175.64
Upside: -
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $29.60
Upside: +21.62%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $142.40
Upside: -